Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
17.85
+0.03 (0.17%)
At close: Apr 14, 2026, 4:00 PM EDT
17.85
0.00 (0.00%)
After-hours: Apr 14, 2026, 7:00 PM EDT
Takeda Pharmaceutical Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Income | 113,185 | 108,143 | 144,197 | 317,038 | 230,166 | 376,171 |
Depreciation & Amortization | 747,026 | 761,396 | 728,002 | 664,400 | 583,151 | 559,671 |
Stock-Based Compensation | 70,691 | 72,867 | 70,871 | 60,672 | 43,374 | 37,663 |
Other Adjustments | 376,518 | 334,667 | 238,872 | 235,055 | 266,825 | -74,454 |
Change in Receivables | 13,496 | -58,959 | 15,104 | 75,127 | 127,294 | -9,316 |
Changes in Inventories | -84,985 | -34,973 | -115,743 | -79,155 | -46,148 | 25,978 |
Changes in Accounts Payable | 2,381 | -7,118 | -9,895 | -84,804 | 125,157 | 36,620 |
Changes in Accrued Expenses | 20 | 45,166 | -126,901 | 31,899 | -58,090 | 49,099 |
Changes in Income Taxes Payable | -156,738 | -150,413 | -202,039 | -185,966 | -140,423 | -201,687 |
Changes in Other Operating Activities | 107,468 | -13,595 | -26,124 | -57,109 | -8,199 | 211,186 |
Operating Cash Flow | 1,189,060 | 1,057,180 | 716,344 | 977,156 | 1,123,110 | 1,010,930 |
Operating Cash Flow Growth | 6.78% | 47.58% | -26.69% | -13.00% | 11.10% | 50.94% |
Capital Expenditures | -178,434 | -200,795 | -175,420 | -140,657 | -123,252 | -111,206 |
Sale of Property, Plant & Equipment | 6,432 | 78 | 8,606 | 962 | 1,815 | 46,453 |
Purchases of Intangible Assets | -264,556 | -178,830 | -305,310 | -493,032 | -62,785 | -125,262 |
Purchases of Investments | -18,645 | -98,540 | -6,766 | -10,151 | -8,341 | -12,596 |
Proceeds from Sale of Investments | 66,562 | 87,133 | 8,021 | 22,254 | 16,921 | 74,604 |
Payments for Business Acquisitions | - | - | - | - | -49,672 | - |
Proceeds from Business Divestments | 43,776 | 20,556 | 19,959 | 7,958 | 28,196 | 530,388 |
Other Investing Activities | 14,027 | 3,337 | -12,951 | 5,564 | -1,008 | -8,851 |
Investing Cash Flow | -330,805 | -367,060 | -463,862 | -607,102 | -198,125 | 393,530 |
Short-Term Debt Issued | 2,710 | 27,490 | 277,000 | 40,000 | -2 | -149,043 |
Net Short-Term Debt Issued (Repaid) | 2,710 | 27,490 | 277,000 | 40,000 | -2 | -149,043 |
Long-Term Debt Issued | 526,060 | 1,024,460 | 100,000 | 75,000 | 249,334 | 1,179,520 |
Long-Term Debt Repaid | -662,419 | -1,321,090 | -320,901 | -356,670 | -810,115 | -1,651,710 |
Net Long-Term Debt Issued (Repaid) | -136,359 | -296,630 | -220,901 | -281,670 | -560,781 | -472,191 |
Repurchase of Common Stock | -101,581 | -51,860 | -2,326 | -26,929 | -77,531 | -2,141 |
Net Common Stock Issued (Repurchased) | -101,581 | -51,860 | -2,326 | -26,929 | -77,531 | -2,141 |
Common Dividends Paid | -312,852 | -302,498 | -287,188 | -279,416 | -283,665 | -283,357 |
Other Financing Activities | -173,035 | -127,925 | -121,000 | -161,134 | -148,286 | -181,622 |
Financing Cash Flow | -721,120 | -751,425 | -354,416 | -709,148 | -1,070,270 | -1,088,350 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 23,673 | -11,385 | 26,204 | 22,929 | 28,758 | 12,501 |
Net Cash Flow | 137,138 | -61,303 | -101,934 | -339,094 | -145,285 | 316,107 |
Free Cash Flow | 1,010,630 | 856,387 | 540,924 | 836,499 | 999,853 | 899,725 |
Free Cash Flow Growth | 18.01% | 58.32% | -35.34% | -16.34% | 11.13% | 65.80% |
FCF Margin | 22.64% | 18.69% | 12.69% | 20.77% | 28.01% | 28.14% |
Free Cash Flow Per Share | 318.17 | 266.73 | 171.14 | 266.42 | 316.98 | 285.89 |
Levered Free Cash Flow | 415,930 | 238,456 | 272,046 | 223,955 | 1,472 | 324,432 |
Unlevered Free Cash Flow | 628,311 | 611,271 | 656,619 | 563,198 | 682,760 | 1,092,750 |
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.